遠距病患監護設備市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

從 2024 年到 2032 年，全球遠端患者監護設備市場的複合年成長率將超過 11.7%。 RPM 設備有助於在傳統臨床環境之外對患者健康狀況進行持續、即時監測。糖尿病、心血管疾病、癌症和慢性腎臟病 (CKD) 等慢性疾病的盛行率激增，大大推動了遠距患者監護設備產業的成長。

例如，世界心臟聯合會(WHF) 的報告強調，2021 年全球心血管疾病(CVD) 死亡人數將達到2,050 萬人。在低收入人群中。

遠端患者監護設備市場根據產品、應用、最終用途和地區進行分組。

市場將產品分為心臟、血壓、神經、多參數、血糖、胎兒和新生兒、睡眠監測設備等。遠距患者監護設備產業的心臟設備部分預計到 2032 年將達到 98 億美元。透過識別心律不整或心臟病等疾病的早期跡象，這些設備不僅可以提高治療成功率，還可以減輕嚴重的併發症。此外，借助先進的感測器和演算法，現代心臟設備可確保精確的指標捕獲，使醫療保健提供者能夠做出明智的、量身定做的治療決策，從而推動遠端患者監護設備市場的成長。

RPM設備的應用領域包括心血管疾病、癌症、糖尿病、神經系統疾病、傳染病、呼吸系統疾病等。 2023 年，光是心血管疾病領域就佔了 30 億美元。鑑於包括高血壓和心臟衰竭在內的心血管疾病是全球發病率和死亡率最高的原因之一，因此持續監測的必要性變得至關重要。 RPM 設備透過提供即時監控，不僅可以及早發現異常情況，還可以預見潛在的併發症，從而能夠及時進行干預。這些功能不僅可以預防嚴重後果，還可以減少住院治療，進一步推動市場成長。

到 2032 年，美國遠距病患監護設備市場預計將達到資料億美元。設備的發展和實施。加拿大公共衛生局強調，糖尿病盛行率激增，2021 年該國 9.4% 的人口（370 萬人）被診斷出糖尿病，性別差異顯著，這進一步加劇了遠端患者監測設備產業的擴張軌跡。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 全球慢性病發生率上升
    • 新興國家可支配收入和醫療保健支出不斷成長
    • 已開發國家的技術進步
    • 越來越多採用遠距患者監護設備
  • 產業陷阱與挑戰
    • 設備成本高
    • 嚴格的監管框架
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 有競爭力的儀表板
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 心臟監測設備
• 血壓監測裝置
• 神經監測設備
• 呼吸監測設備
• 多參數監測裝置
• 血糖監測設備
• 胎兒和新生兒監測設備
• 睡眠監測設備
• 其他監控設備

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 心血管疾病
• 癌症
• 糖尿病
• 神經系統疾病
• 傳染病
• 呼吸系統疾病
• 其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 居家照護環境
• 長期照護
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 波蘭
  • 瑞士
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 泰國
  • 印尼
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 哥倫比亞
  • 智利
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• Cerner Corporation
• Baxter International Inc.
• Boston Scientific Corporation
• DexCom, Inc.
• F. Hoffmann-La Roche Ltd
• General Electric Company
• Johnson and Johnson
• Koninklijke Philips NV
• Medtronic plc
• OMRON Corporation
• Siemens Healthineers AG
• VitalConnect

The Global Remote Patient Monitoring Devices Market will show over 11.7% CAGR from 2024 to 2032. RPM devices facilitate the continuous, real-time monitoring of patient's health outside conventional clinical environments. The surging prevalence of chronic ailments, including diabetes, cardiovascular diseases, cancer, and chronic kidney disease (CKD), significantly propels the growth of the remote patient monitoring devices industry.

For instance, a report from the World Heart Federation (WHF) highlighted those global fatalities from cardiovascular diseases (CVD) reached 20.5 million in 2021. CVD topped the global mortality chart in 2021, with a staggering 80% of these deaths occurring in low- and middle-income nations.

The Remote Patient Monitoring Devices Market is grouped based on product, application, end use , and region.

The market categorizes products into cardiac, blood pressure, neurological, multiparameter, blood glucose, fetal and neonatal, sleep monitoring devices, and others. The cardiac devices segment of the remote patient monitoring devices industry is projected to hit USD 9.8 billion by 2032. These devices monitor heart rhythms and rates in real-time, ensuring prompt medical intervention when anomalies arise. By identifying early signs of conditions like arrhythmias or heart attacks, these devices not only enhance treatment success rates but also mitigate severe complications. Furthermore, with advanced sensors and algorithms, modern cardiac devices ensure precise metric capture, empowering healthcare providers to make informed, tailored treatment decisions, thus fueling remote patient monitoring devices market growth.

The application segment of RPM devices encompasses cardiovascular diseases, cancer, diabetes, neurological disorders, infectious diseases, respiratory ailments, and more. In 2023, the cardiovascular diseases segment alone accounted for a substantial USD 3 billion. Given that CVDs, including hypertension and heart failure, rank among the top global morbidity and mortality causes, the need for continuous monitoring becomes paramount. RPM devices, by offering real-time monitoring, not only detect abnormalities early but also foresee potential complications, enabling timely interventions. Such capabilities not only prevent severe outcomes but also reduce hospitalizations, further propelling market growth.

The U.S. remote patient monitoring devices market is on track to reach USD 14.8 billion by 2032. As a frontrunner in technological advancements, the U.S. boasts a robust infrastructure-comprising high-speed internet, advanced data centers, and state-of-the-art technology platforms-that nurtures the evolution and implementation of sophisticated RPM devices. The surging diabetes prevalence, highlighted by the Public Health Agency of Canada, where 9.4% of the population (3.7 million) were diagnosed in 2021, with a notable gender disparity, further accentuates the expansion trajectory of the remote patient monitoring devices industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases across the globe
    • 3.2.1.2 Growing disposable income and healthcare expenditure in emerging countries
    • 3.2.1.3 Technological advancement in developed nations
    • 3.2.1.4 Growing adoption of remote patient monitoring devices
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of devices
    • 3.2.2.2 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive dashboard
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cardiac monitoring devices
• 5.3 Blood pressure monitoring devices
• 5.4 Neurological monitoring devices
• 5.5 Respiratory monitoring devices
• 5.6 Multiparameter monitoring devices
• 5.7 Blood glucose monitoring devices
• 5.8 Fetal and neonatal monitoring devices
• 5.9 Sleep monitoring devices
• 5.10 Other monitoring devices

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular diseases
• 6.3 Cancer
• 6.4 Diabetes
• 6.5 Neurological disorders
• 6.6 Infectious diseases
• 6.7 Respiratory diseases
• 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Home-care settings
• 7.3 Long-term care
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Russia
  • 8.3.7 Poland
  • 8.3.8 Switzerland
  • 8.3.9 Netherlands
  • 8.3.10 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Thailand
  • 8.4.7 Indonesia
  • 8.4.8 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Colombia
  • 8.5.5 Chile
  • 8.5.6 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Israel
  • 8.6.5 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Cerner Corporation
• 9.3 Baxter International Inc.
• 9.4 Boston Scientific Corporation
• 9.5 DexCom, Inc.
• 9.6 F. Hoffmann-La Roche Ltd
• 9.7 General Electric Company
• 9.8 Johnson and Johnson
• 9.9 Koninklijke Philips N.V
• 9.10 Medtronic plc
• 9.11 OMRON Corporation
• 9.12 Siemens Healthineers AG
• 9.13 VitalConnect